Drug-induced torsades de pointes in patients aged 80 years or more
- PMID: 18676301
Drug-induced torsades de pointes in patients aged 80 years or more
Abstract
Objective: We studied all English-written peer-reviewed reports on drug-induced torsades de pointes (TdP) in patients aged 80 years or more in order to characterize the clinical circumstances leading to this serious complication.
Methods: Our literature search yielded 24 reports on 25 patients aged 80-95 years with drug-induced TdP. We systematically reviewed each report and recorded the non-modifiable risk factors for drug-induced TdP (i.e., female sex and structural heart disease) as well as preventable clinical circumstances, which might have been associated with drug-induced TdP.
Results: The most prevalent risk factors for drug-induced TdP were non-modifiable risk factors: 22 (88%) patients were female patients and 19 (76%) patients had structural heart disease. Overall, 16 (64%) patients were female patients with structural heart disease. The literature did not report any elderly male patients without structural heart disease. Among the preventable clinical circumstances, which might have been associated with drug-induced TdP, the most prevalent were: administrating QT prolonging agents despite long QT interval (n=11; 44%) and co-administration of two or more QT prolonging agents (n=9; 36%). The most prevalent QT prolonging agents found to trigger TdP were macrolides and quinolones (n=9; 36%). All but three patients had at least one or more preventable clinical circumstances, which might have been associated with drug-induced TdP.
Conclusion: Physicians should be more aware of the risk for drug-induced TdP in patients aged 80 years or more while administrating QT prolonging agents despite long QT interval and co- administrating two or more QT prolonging agents, specifically in elderly female patients with structural heart disease.
Similar articles
-
Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?J Electrocardiol. 2009 Jul-Aug;42(4):353-357.e1. doi: 10.1016/j.jelectrocard.2009.01.005. Epub 2009 Mar 3. J Electrocardiol. 2009. PMID: 19261294
-
A case series of drug-induced long QT syndrome and Torsade de Pointes.Singapore Med J. 2001 Dec;42(12):566-70. Singapore Med J. 2001. PMID: 11989578
-
QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.Anticancer Drugs. 2007 Apr;18(4):493-8. doi: 10.1097/CAD.0b013e328012d023. Anticancer Drugs. 2007. PMID: 17351403
-
Proarrhythmic potential of antimicrobial agents.Infection. 2008 Jun;36(3):194-206. doi: 10.1007/s15010-007-7211-8. Epub 2008 May 3. Infection. 2008. PMID: 18454341 Review.
-
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.Acta Psychiatr Scand. 2005 Mar;111(3):171-6. doi: 10.1111/j.1600-0447.2004.00469.x. Acta Psychiatr Scand. 2005. PMID: 15701100 Review.
Cited by
-
Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.Drugs. 2010 Mar 26;70(5):573-603. doi: 10.2165/11535230-000000000-00000. Drugs. 2010. PMID: 20329805 Review.
-
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22. Z Gerontol Geriatr. 2018. PMID: 27878411 Review. English.
-
Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Eur J Clin Pharmacol. 2012 May;68(5):479-503. doi: 10.1007/s00228-011-1161-x. Epub 2011 Nov 22. Eur J Clin Pharmacol. 2012. PMID: 22105373 Review.
-
Levofloxacin-induced torsades de pointes.Tex Heart Inst J. 2010;37(2):216-7. Tex Heart Inst J. 2010. PMID: 20401298 Free PMC article.